HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
The AHA’s social media toolkit for spreading awareness of the flu focuses on the beginning of fall and the availability of the flu vaccine for at-risk,…
Headline
Measles cases have been reported by 42 states and jurisdictions this year, with 1,563 total nationwide, according to the latest data released yesterday by the…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
AHA’s latest social media toolkit for spreading awareness of the flu focuses on the availability of the flu vaccine for at-risk, vulnerable populations as flu…
Headline
The Centers for Disease Control and Prevention Sept. 24 released its annual report on national sexually transmitted disease data, reporting a 9% decline in STD…
Headline
The flu hospitalization rate during the 2024-25 flu season was the highest since 2010-11, according to a report published Sept. 12 by the Centers for Disease…